跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NEXVIAZYME - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NEXVIAZYME
Authorized
STANDARD
NEXVIAZYME
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
53674eb40a165345
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
53674eb40a165345
Drug Approval Canada Name
NEXVIAZYME
Product Name
NEXVIAZYME
Status
Marketed
Status Date
2022-02-09
Original Market Date
2022-02-09
Din
02522365
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
44:00.00
Atc Original
A16AB22 AVALGLUCOSIDASE ALFA
Atc Name
a 16 ab 22
Aig Number
0163274001
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
AVALGLUCOSIDASE ALFA
100 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
53674eb40a165345
Type
Standard
Back to Health Canada Approvals